Cash and Cash Equivalents (USD, millions)

Accounts Receivable, less allowances (USD, millions)

Inventories (USD, millions)

Other Current Assets (USD, millions)

Total Current Assets (USD, millions)

Property, Plant and Equipment, Net (USD, millions)

Acquisition-related Intangible Assets, Net (USD, millions)

Other Assets (USD, millions)

Goodwill (USD, millions)

Total Assets (USD, millions)

Short-term Obligations and Current Maturities of Long-term Obligations (USD, millions)

Total Current Liabilities (USD, millions)

Other Long-term Liabilities (USD, millions)

Long-term Obligations (USD, millions)

Redeemable Noncontrolling Interest (USD, millions)

Total Equity (USD, millions)

Total Liabilities, Redeemable Noncontrolling Interest and Equity (USD, millions)

b041a97ab885ed6db9d573768e02ad03da17de99e44cde0816b9736fadd407a3

Net income (USD, millions)

Depreciation of property, plant and equipment (USD, millions)

Amortization of acquisition-related intangible assets (USD, millions)

Change in deferred income taxes (USD, millions)

Other non-cash expenses, net (USD, millions)

Changes in assets and liabilities, excluding the effects of acquisitions (USD, millions)

Net cash provided by operating activities (USD, millions)

Purchases of property, plant and equipment (USD, millions)

Proceeds from sale of property, plant and equipment (USD, millions)

Proceeds from cross-currency interest rate swap interest settlements (USD, millions)

Purchases of investments (USD, millions)

Other investing activities, net (USD, millions)

Net cash used in investing activities (USD, millions)

Net proceeds from issuance of debt (USD, millions)

Repayment of debt (USD, millions)

Purchases of company common stock (USD, millions)

Dividends paid (USD, millions)

Other financing activities, net (USD, millions)

Net cash used in financing activities (USD, millions)

Exchange rate effect on cash (USD, millions)

Decrease in cash, cash equivalents and restricted cash (USD, millions)

Cash, cash equivalents and restricted cash at beginning of period (USD, millions)

Cash, cash equivalents and restricted cash at end of period (USD, millions)

49378e6431872b5fa6d6fc7d8b46f20b9a113578c98a1a4776bfc197506beedc

Total revenues (USD, millions)

Selling, general and administrative expenses (USD, millions)

Research and development expenses (USD, millions)

Restructuring and other costs (USD, millions)

Total costs and operating expenses (USD, millions)

Operating income (USD, millions)

Interest income (USD, millions)

Interest expense (USD, millions)

Other income/(expense) (USD, millions)

Income before income taxes (USD, millions)

Provision for income taxes (USD, millions)

Equity in earnings/(losses) of unconsolidated entities (USD, millions)

Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest (USD, millions)

Net income attributable to Thermo Fisher Scientific Inc. (USD, millions)

Basic earnings per share attributable to Thermo Fisher Scientific Inc. (USD)

Diluted earnings per share attributable to Thermo Fisher Scientific Inc. (USD)

d93fe731cf09f1fc45667419af3f7f6e2027127169a404614ae2a3edae19a3d9

36f9101ec0538e28989fe65629cbe6cfbb8d9c48218fdb74b14caa222b63c1d4

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

dfbdf6c6c2adfa97f788675cc969fe1d97d9030e9d7004ceb87b091b5f48808f

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

187423730e664bbdee8b07d5e3b8b7e95d5dc0edf245fd5a48138f7519b78239

Organic revenue growth for Life Sciences Solutions (percent)

Organic revenue growth for Analytical Instruments (percent)

Organic revenue growth for Specialty Diagnostics (percent)

Organic revenue growth for Laboratory Products and Biopharma Services (percent)

Organic revenue growth (percent)

9a331741905ff64bb6ff8b89f4b959e628d7324cf47234e33f5b37aa2f7069d8

28ab49beabb5557c233efbd58e33699954773f154c3fb36b2655e7f855eea415

North America

- United States

Europe

Asia-Pacific

Other Regions

- Other Countries

Total Revenue

6986f6ed99b123b3922930d1c7c937eba4bd43c8302d9a8aded99a3d4096b7e0

THERMO FISHER SCIENTIFIC (TMO)

Financials